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Abstract
The effectiveness of the potent antifungal drug fluconazole is being compromised by the rise of
drug-resistant fungal pathogens. While inhibition of Hsp90 or calcineurin can reverse drug
resistance in Candida, such inhibitors also impair the homologous human host protein and fungal-
selective chemosensitizers remain rare. The MLPCN library was screened to identify compounds
that selectively reverse fluconazole resistance in a Candida albicans clinical isolate, while having
no antifungal activity when administered as a single agent. A piperazinyl quinoline was identified
as a new small molecule probe satisfying these criteria.
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Acquired drug resistance by medically relevant microorganisms poses a grave threat to
human health and has enormous economic consequences.1–3 Fungal pathogens present a
particular challenge because they are eukaryotes and share many of the same mechanisms
that support the growth and survival of the human host cells they infect. While
contemporary antifungal medications such as fluconazole remain effective, the usefulness of
such drugs is compromised by either dose-limiting host toxicity or the frequent emergence
of high-grade resistance.2,3
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The opportunistic fungus Candida albicans preferentially invades immunocompromised
individuals and is responsible for numerous cutaneous, mucosal, and systemic blood-borne
infections annually.4 The azole antifungal fluconazole is often prescribed to control such
infections, but fluconazole’s fungistatic nature and emerging resistance are beginning to
detract from its effectiveness. Typically, a daily regimen of 100 mg is sufficient to treat
infections, but dosages as high as 800 mg/day can be ineffective against fluconazole-
resistant C. albicans.5
Chemosensitizing Candida albicans to fluconazole is one approach to combat the emerging
resistance of this pathogen. A limited number of small molecules have demonstrated modest
potential in this arena,6–11 and the proteins Hsp90 and calcineurin appear integral to some of
the resistance pathways utilized by Candida.12 This tentative progress towards stemming the
increasing fluconazole resistance of Candida prompted us to screen the National Institutes
of Health Molecular Libraries Probe Production Centers Network (NIH-MLPCN) compound
collection with the goal of identifying small molecules that act as fungal-selective
chemosensitizers and could be used to probe the various antifungal resistance mechanisms
of Candida.
A high throughput screen of ~300,000 compounds evaluated growth inhibition of the C.
albicans clinical isolate CaCi-25 in the presence of a sub-lethal concentration of fluconazole
(Figure 1, PubChem AID 1979).13 1,893 compounds exhibited >75% inhibition when dosed
at 9.5 μM, of which 622 possessed IC50 values less than 1 μM when tested in a dose-
response assay.
An orthogonal screen evaluated the efficacy of these 622 hits in combination with
fluconazole against a more resistant C. albicans clinical isolate CaCi-8,5,13 selecting for
compounds that were active with IC50’s below 50 μM. At this stage, 403 compounds were
identified as chemosensitizers of both CaCi-2 and CaCi-8.
To remove hits with undesirable activity profiles, two counterscreens were incorporated into
the late stages of the screening campaign. The first employed murine 3T3 fibroblasts to
assay non-selective mammalian cell toxicity while reevaluating CaCi-2 in the absence of
fluconazole identified inherently fungitoxic substances. 296 of 403 candidates successfully
passed both counterscreens, and the piperazinyl quinoline 1 (Figure 1) was selected for
further investigation as a potential probe.
A number of analogs structurally related to 1 were prepared and evaluated for their ability to
reverse fluconazole resistance in the C. albicans test strains. Two critical intermediates 5
and 6 were prepared by reacting excess piperazine with either 4-chlorobenzoic acid or 4,7-
dichloroquinoline (Scheme 1). Amide coupling of piperazinyl quinoline 5 with different
carboxylic acids afforded analogs 7. Similarly, acylated piperazine 6 was appended to
various aryl chlorides and bromides to provide analogs 8.
Upon their preparation, the resulting collection of analogs was tested for their ability to
increase fluconazole susceptibility in CaCi-2 and CaCi-8. The fungi were incubated at 37 °C
for 48 hours with the test compound and 8 μg/mL fluconazole before growth inhibition was
assessed by Alamar blue fluorometry. Geldanamycin, a non-selective Hsp90 inhibitor, was
used as a control for growth inhibition (100% inhibition at 10 μM).12 The different analogs
were also screened against mammalian fibroblasts and CaCi-2 in the absence of fluconazole
to identify substances with intrinsic toxicity or antifungal effects. In the absence of
fluconazole, none of the analogs showed any appreciable activity against CaCi-2 (IC50 =
15–26 μM) and were non-toxic to fibroblasts as well (IC50 = 21–26 μM).
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The chemosensitizing properties of select 4-chlorobenzamide analogs 7 on CaCi-2 and
CaCi-8 are presented in Table 1. The initial hit 1 proved to be an effective chemosensitizer
of both fungal strains (IC50 = 0.7 and 1.3 μM, respectively) but suffered from poor
solubility. Attempts to incorporate alternative para-substituents typically lowered the
effectiveness of the resulting compounds as demonstrated with 7a–c. Similarly, relocation of
the chloro substitutent to the meta or ortho positions (e.g. 7d–e) was not tolerated, although
the 3,4-dichloro variant 7f displayed levels of activity comparable to the original hit.
Amides derived from alkanoic acids were significantly more soluble than 1 but were less
effective chemosensitizers. Analogs bearing linear (7h), branched (7i), and cyclic (7j–k)
alkyl chains were partial growth inhibitors of CaCi-2 at micromolar concentrations.
However, the cycloalkane amides 7j–k displayed greater effectiveness against the more
resistant CaCi-8 strain than their acyclic counterparts (7h–i). Ureas such as 7l were prepared
from reacting 6 with different isocyanates and showed only moderate growth inhibition
against CaCi-2 when dosed with fluconazole. Sulfonamides did not increase fluconazole
susceptibility of either CaCi-2 or CaCi-8 (data not shown).
Several heteroaromatic replacements of the 4-chlorophenyl ring were also prepared. As
observed with the alkanamides, compounds such as 7m–o were more soluble in PBS
solution but possessed lower potencies relative to 1. Despite its poor aqueous solubility, the
4-chlorophenyl amide remained the most effective functional group among the several
dozen variants evaluated, and its efficacy in the cellular assays suggests 1 may possess a
high binding affinity for its target.
Next, the role of the 7-chloroquinoline fragment was investigated, and several representative
analogs that were prepared are summarized in Table 2. Initially, alternatives to chlorine were
introduced into the ring system, and the specific sites of substitution were varied as well.
Analogs 8a–d represent some of the permutations considered, but none were able to match
the effectiveness of 1. In addition, this series of compounds did little toimprove solubility.
Ultimately, our efforts to modify the quinoline system were unfruitful; the 7-chloro
derivative still offered the greatest cellular potency against both CaCi-2 and CaCi-8.
In order to circumvent the steep SAR associated with the quinoline scaffold, a series of
nitrogen heterocycles were explored as surrogates. The various replacements often resulted
in large increases in solubility but these gains were offset by diminished activity. Truncating
the quinoline system to the analogous pyridines (8e–g) essentially negated all cellular
activity. Similarly, related heterocycles such as pyridazine 8h, pyrimidine 8i, and pyrazine
8j were marginal inhibitors of C. albicans growth. Bicyclic systems such as 8k and 8l
showed weak inhibition against both Candida strains, and this activity trend was also
observed for the smaller, monocyclic imidazole and thiazole counterparts (8m–n). The 4-
chlorobenzene derivative 8o was one of several phenyl analogs prepared; compounds of this
class were ineffective growth inhibitors.
Compound 1 was determined to be the most effective chemosensitizer of C. albicans CaCi-2
and CaCi-8 in cellular assays with IC50 values of 0.7 and 1.3 μM, respectively. Aqueous
solubility remains a liability for this compound, and all attempts to increase solubility
reduced cellular activity. 1 had no discernible effect on CaCi-2 in the absence of
fluconazole, and murine 3T3 fibroblasts showed no response up to 26 μM. To provide
insight into possible modes of action, 1 was evaluated in yeast reporter assays for potential
inhibitory activity against Hsp90-dependent and calcineurin-dependent signaling pathways.
Inhibition of these pathways has been linked to lower fluconazole resistance in Candida,12
but compound 1 did not affect either mechanism (IC50 >26 μM), suggesting that it may
exploit an alternative pathway to reverse fluconazole resistance in C. albicans. Target
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identification via resistance studies are ongoing and will hopefully uncover novel fungal
stress response pathways that could further yield additional therapeutic targets for future
generations of antifungals.
The current work evaluated over 300,000 compounds of the NIH-MLPCN collection to
identify agents capable of reversing fluconazole resistance in clinical isolates of Candida
albicans. After triage through a series of counterscreens and an orthogonal assay, 296
substances with the ability to sensitize two Candida albicans clinical isolates towards
fluconazole treatment were identified. Piperazinyl quinoline 1 was selected for further SAR
investigation and optimization efforts. As a result of these synthetic studies, compound 1
emerged as the most effective chemosensitizer, able to achieve full growth inhibition of both
CaCi-2 (97–100% inhibition) and the more resistant CaCi-8 (97–100% inhibition) at
approximately 1 μM. In addition, it was determined that 1 was not inherently toxic or
fungicidal and did not act via two established resistance paths. This compound has been
registered with NIH Molecular Libraries Program (probe ML 189) and is available upon
request.14
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Summary of HTS campaign of the MLPCN ~300,000 compound collection. The selection
criterion for each assay is given in parentheses
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Synthesis of analogs. Reagents and conditions: a) Et3N, 130 °C; b) EDCI, DMAP, CH2Cl2;
c) R-CO2H, EDCI, DMAP, CH2Cl2; d) RNCO, CH2Cl2; e) ArCl, Et3N, 130 °C; f) ArBr,
NaOt-Bu, 15 mol% BINAP, 5 mol% Pd2(dba)3, toluene, 80 °C.
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Table 1




1 0.7 ± 0.5 1.3 ± 1.6
7a 2.3 ± 1.0 3.1 ± 2.8
7b 5.3 ± 1.1 16.8 ± 9.3
7c 3.6 ± 2.3 4.2 ± 2.7
7d 4.4 ± 2.1 7.8 ± 5.6
7e 7.3 ± 3.2 14.1 ± 7.2
7f 1.0 ± 0.6 2.1 ± 1.8
7g 4.4 ± 3.1 6.1 ± 4.4
7h 6.3 ± 4.4 15.0 ± 11.6

















7i 7.2 ± 3.8 >26.0
7j 3.6 ± 2.4 5.3 ± 4.1
7k 1.7 ± 1.1 4.0 ± 2.7
7l 4.2 ± 2.2 2.3 ± 2.5
7m 6.7 ± 3.2 10.9 ± 9.0
7n 4.9 ± 2.3 4.1 ± 3.0
7o 1.9 ± 0.9 4.0 ± 3.0
a
CaCi-2 and CaCi-8 cells were incubated at 37 °C for 48 hours with test compound and 8 μg/mL fluconazole.
b
Average of at least three runs
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Table 2




1 0.7 ± 0.5 1.3 ± 1.6
8a 2.4 ± 1.9 6.3 ± 6.1
8b 4.8 ± 2.8 13.7 ± 4.7
8c 7.3 ± 4.9 >26.0
8d 5.7 ± 4.2 14.7 ± 8.2
8e >10.0 24.0 ± 3.5
8f 7.3 ± 4.9 >26.0
8g 7.3 ± 4.9 >26.0
8h 8.5 ± 6.0 20.6 ± 10.8

















8i 7.1 ± 5.8 18.1 ± 10.9
8j 9.0 ± 3.5 22.2 ± 7.7
8k 4.8 ± 2.2 11.0 ± 9.0
8l 5.5 ± 4.9 10.8 ± 13.2
8m 6.2 ± 5.7 >26.0
8n 6.9 ± 5.9 18.9 ± 10.5
8o 8.7 ± 3.9 19.0 ± 21.4
a
CaCi-2 and CaCi-8 cells were incubated at 37 °C for 48 hours with test compound and 8 μg/mL fluconazole.
b
Average of at least three runs
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